Business Description
CNS Pharmaceuticals is a Houston-based company founded in 2017, focused on finding new ways to treat cancerous brain tumors. Its two main experimental treatments, TPI 287 and Berubicin, are currently being tested in advanced human trials targeting some of the most aggressive forms of brain cancer. The company works alongside Cortice Biosciences under a formal licensing arrangement to advance its research goals.
